This has reference to the meeting of Board of Directors held on 4th February 2025 inter alia considered and approved: 1. Unaudited Financial Results for the quarter and nine months ended on 31st December 2024 along with Limited Review report. 2. The Board of Directors of the Company, based on a legal opinion, has resolved to write off the time-barred unsecured Foreign Currency Convertible Bond (FCCB) liability of ?38.68 crores including interest, which has remained unclaimed for over 10 years and is no longer legally enforceable under applicable laws.

pdf

Venus Remedies Ltd.

24 Jan 2025

470.00

1.57%

Board Meeting

VENUS REMEDIES LTD. - 526953 - Board Meeting Intimation for Board Meeting Scheduled To Be Held …

BSE India

VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2025 ,inter alia, to consider and approve Board meeting scheduled to be held on 04th February 2025

pdf

Venus Remedies Ltd.

20 Jan 2025

470.00

1.57%

Company Update

VENUS REMEDIES LTD. - 526953 - Venus Remedies Limited Successfully Renews EU GMP

BSE India

Venus Remedies Limited successfully renews EU GMP

pdf

Venus Remedies Ltd.

07 Jan 2025

470.00

1.57%

Company Update

VENUS REMEDIES LTD. - 526953 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Compliance under reg 74(5) of SEBI DP regulations.

pdf

Venus Remedies Ltd.

31 Dec 2024

470.00

1.57%

Company Update

VENUS REMEDIES LTD. - 526953 - Venus Remedies Limited Expands Reach In Eastern European Market With …

BSE India

Venus Remedies Limited expands reach in Eastern European market with accreditation of Good Manufacturing Practice (GMP) certification from Ministry of Health Moldova

pdf